Investor Presentation First Nine Months of 2023
123
Investor presentation
First nine months of 2023
Region China at a glance.
Region China
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
MS
First nine months of
2023
Sales
(mDKK)
Growth²
200
6%
Injectable GLP-13
4,843
94%
14%
30
100%
160
RybelsusⓇ
96
171%
GLP-1
87.0%1
80%
Total GLP-1
4,939
95%
120
20
20
Insulin
Total insulin4
6,907
-10%
0.5%¹
60%
175
Other Diabetes care5
705
-21%
80
164
141
40%
Diabetes care
12,551
13%
10
40
40
8.4%¹
OAD
Obesity care
129
25%
20%
Diabetes & Obesity care
12,680
13%
0
2021
0
0%
2030
2045
Aug
2018
Population with diabetes
Diabetes growth rate
Aug
2023
Rare disease?
Total
589
-13%
13,269
12%
-GLP-1 MS
-Insulin MS
OAD MS
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2023: Novo Nordisk 52%,
Others 48%; Competitor GLP-1 value market shares, as of Aug 2023: Novo
Nordisk 75% and Others 25% OAD: Oral anti-diabetic; MS: Market Share;
Source: IQVIA MAT, Aug 2023 value figures; Market values are based on the
list prices
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ; 4
Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6Comprises SaxendaⓇ; Comprises
primarily NovoSeven®, Novo Eight® and NorditropinⓇView entire presentation